Skip to Main Content
Contribute Try STAT+ Today

Good morning, everyone, and how are you today? We are just fine, thank you, especially since the Pharmalot campus is unusually quiet this morning, since the short person is elsewhere, enjoying a mini-break from the local schoolhouse. As for us, we are pursuing our usual routine and relying on cups of stimulation for assistance. In the interest of full disclosure, our choice is apple cider donut. Feel free to join us. Meanwhile, there is much to do and, no doubt, you can relate. This is a busy time, yes? So here are some tidbits.

President Trump is expected to name former Eli Lilly (LLY) executive Alex Azar to lead the Department of Health and Human Services, according to various reports. Azar, who worked at the drug maker for much of the past decade, was president of Lilly U.S. operations until earlier this year, and served as HHS Deputy Secretary under former President George W. Bush.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Athenex objects … novel to have a pharma company complain about an (most probably) off-label use, if I may observe.

Comments are closed.